Genomics News and Research

RSS

Genomics is the study of the complete genetic material, including genes and their functions, of an organism.

Major breakthrough may help develop low toxicity drugs for sleeping sickness

Scientists from the Drug Discovery Unit at the University of Dundee - working together with partners at the University of York and the Structural Genomics Consortium in Toronto - have made a major breakthrough in identifying new treatments for a fatal disease which infects tens of thousands of Africans each year.

1 Apr 2010

GeneLink's net sales for fourth-quarter of 2009 increased by 9.7%

GeneLink, Inc., a leading consumer genomics biotech company, today reported financial results for the fiscal year ended December 31, 2009.

1 Apr 2010

Rosetta Genomics reports revenues of $150,000 for full-year 2009

Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, today reported that on March 26, 2010 the Company filed its Form 20-F with the U.S. Securities and Exchange Committee, which contains financial results for the three and 12 months ended December 31, 2009.

31 Mar 2010

Feinstein Institute scientists seek sisters for lupus study

The SisSLE (Sisters of Women with Systemic Lupus Erythematosus) research study is looking for sisters: one with a diagnosis of systemic lupus erythematosus (SLE), an autoimmune disease and one (or more) who does not have lupus.

31 Mar 2010

CLC bio signs partnership agreement with Ion Torrent

CLC bio, the world's leading bioinformatics solution provider, today announced a partnership with Ion Torrent, a new sequencing company started by Dr. Jonathan Rothberg, the founder of 454 Life Sciences. The partnership will ensure that data can directly flow off of the Ion Personal Genome Machine sequencer and into CLC bio's solutions, like CLC Genomics Workbench or CLC Genomics Server.

30 Mar 2010

Development and validation process of Rosetta Genomics' miRview mets published

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostics, announces publication of an article describing the development and validation process of miRview™ mets, the company's microRNA-based test for identification of primary origin of metastases.

30 Mar 2010

New Prestige Antibodies powered by Atlas Antibodies added to Sigma Life Science's portfolio

Sigma® Life Science, the innovative biological products and services brand of Sigma-Aldrich®, today announced that it has added 2,200 new Prestige Antibodies® powered by Atlas Antibodies to its industry-leading portfolio.

From Atlas Antibodies 29 Mar 2010

Pathway Genomics Genetic Health Report helps make more informed health and lifestyle decisions

You may not suffer from any form of heart disease, high blood pressure, or high cholesterol, but you could have a predisposition for these conditions based on more than just your lifestyle or diet. A family history of diabetes, gout, high blood pressure or high blood cholesterol can increase one’s risk regardless of lifestyle.

27 Mar 2010

Dell unveils Medical Archiving and PowerEdge C 6100 solutions to boost healthcare efficiency

Dell today unveiled solutions to enable healthcare, higher-education and government organizations to better use technology to manage data, conduct research and fulfill their missions in a more efficient and secure manner.

26 Mar 2010

Roche NimbleGen' s microarray technologies help identify genes responsible for CRC

In a recently published study in the journal Genome Research, a team of scientists led by Dr. Shaying Zhao at the University of Georgia have developed a novel cross-species comparative genomics and oncology strategy for cancer driver gene discovery, using microarray technologies from Roche NimbleGen, that differs fundamentally from current approaches which focus on human cancers only.

26 Mar 2010

ASCO, ESMO and OECI endorse WIN Symposium's initiatives on improving outcomes of cancer

The WIN Consortium, supported by its media partner Nature Publishing Group, has opened registration for the second annual WIN Symposium, to be held in the Palais des Congrès, Paris, on the 7th to 9th of July 2010. The WIN Symposium is an open and interactive forum designed to promote rapid translation of ground-breaking personalized cancer medicine discoveries to clinical practice.

25 Mar 2010

Agendia brings new personalized treatment for breast cancer patients

Agendia, a world leader in molecular cancer diagnostics, today announced that its breast cancer product offering, consisting of breast cancer recurrence test MammaPrint(R), and TargetPrint(TM), has been expanded with BluePrint (TM) to report important additional information on tumor subtypes.

24 Mar 2010

GENETICS 2010 meeting highlights latest research on human genetic disorders

The Genetics Society of America (GSA) biennial meeting, "GENETICS 2010: Model Organisms to Human Biology," June 12-15, 2010, at the Sheraton Boston, Massachusetts, will bring together investigators who study genetic models in organisms such as flies, yeast, fungi, mice and other non-human organisms, with researchers in human genetics

24 Mar 2010

T1D and IBD may respond to 2-way genetic switch: Study

Pediatric researchers analyzing DNA variations in type 1 diabetes and inflammatory bowel disease have found a complex interplay of genes. Some genes have opposing effects, raising the risk of one disease while protecting against the other. In other cases, a gene variant may act in the same direction, raising the risk for both diseases.

23 Mar 2010

Undiagnosed autistic traits deny children needed support

There has been a major increase in the incidence of autism over the last twenty years. While people have differing opinions as to why this is (environment, vaccines, mother's age, better diagnostic practice, more awareness etc.) there are still many children who have autistic traits that are never diagnosed clinically. Therefore, they do not receive the support they need through educational or health services.

23 Mar 2010

Genes allowing opium poppy to make codeine and morphine discovered

Researchers at the University of Calgary have discovered the unique genes that allow the opium poppy to make codeine and morphine, thus opening doors to alternate methods of producing these effective painkillers either by manufacturing them in a lab or controlling the production of these compounds in the plant.

18 Mar 2010

Berkeley HeartLab adopts GenTegra DNA to support diagnostic genetic testing for cardiovascular disease

GenVault Corporation today announced that Berkeley HeartLab, a subsidiary of Celera Corporation, has adopted GenTegra DNA to preserve and store diagnostic samples for genetic testing related to the management of cardiovascular disease.

18 Mar 2010

Agendia to participate in groundbreaking clinical trial for breast cancer

Agendia, a world leader in molecular cancer diagnostics, announced today it will participate in the highly anticipated I-SPY 2 TRIAL for breast cancer, set to launch at the first of nearly twenty research sites.

18 Mar 2010

Finding right balance between high-throughput sequencing and related bioinformatics analysis

Balancing high-throughput sequencing and related bioinformatics analysis between a research group’s internal efforts and specialized service providers can both speed results to difficult biological questions and provide cost-effective access to the latest technology, says Eureka Genomics (EG). The company’s unique capabilities and services and how they can help in “Finding the Right Balance” will be the topic of discussion at a “Java and Jive” session on Wednesday March 17, 8:15 am at the Now-Generation Sequencing conference being held at the Hilton San Diego Resort in San Diego, CA.

17 Mar 2010

Clarient's Ovotax test may help improve patients’ response to taxane therapy

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that data from a new study shows that Clarient's Ovotax™ assay may effectively predict which ovarian cancer patients will respond favorably to taxane therapy and could, therefore, be spared the potential side effects of this rigorous and sometimes toxic chemotherapy agent.

17 Mar 2010